Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)
Liselore Loverix, Ignace Vergote, Pieter Busschaert, Adriaan Vanderstichele, Bram Boeckx, Tom Venken, Philipp Harter, Hilde Brems, Els Van Nieuwenhuysen, Sandro Pignata, Thaïs Baert, Antonio González-Martı́n, Sileny Han, Christian Marth, Patrick Neven, Nicoletta Colombo, Patrick Berteloot, Johanna Mäenpää, Siel Olbrecht, Tina Laga, Erwin Sablon, Isabelle Ray‐Coquard, Éric Pujade-Lauraine, Diether Lambrechts, Toon Van Gorp
Topics & Concepts
MedicineOvarian cancerOlaparibOncologyInternal medicinePARP inhibitorCancerBRCA mutationGeneticsBiologyDNAPoly ADP ribose polymerasePolymerasePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancer